ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...
ABBOTT PARK, Ill., June 20, 2011 /PRNewswire/ -- Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron ...
Abbott announced that the US Food and Drug Administration (FDA) has approved two new strengths for three-month administration of Lupron Depot-PED (leuprolide acetate for depot suspension) for the ...
Abbott announced that the FDA has approved Lupron Depot-PED (leuprolide acetate for depot suspension) 11.25mg and 30mg for three-month administration for the treatment of children with central ...
ABBOTT PARK, Ill., Aug. 16, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) announced today that the U.S. Food and Drug Administration (FDA) has approved two new strengths for three-month administration of ...
The US Food and Drug Administration (FDA) have approved Abbott’s supplemental New Drug Application (sNDA) for Lupron Depot-PED (leuprolide acetate for depot suspension). The one-month formulation is ...
Cipla Limited and its wholly owned subsidiary Cipla USA Inc. on Tuesday has announced the launch of Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the United States Food and ...
The FDA is reviewing Abbott’s supplemental New Drug Application for a new six-month 45-mg formulation of Lupron Depot (leuprolide acetate for depot suspension) for the palliative treatment of advanced ...
Cipla has launched Leuprolide Acetate Injection Depot 22.5mg. The product was approved by the United States Food and Drug Administration (US FDA) based on a New Drug Application (NDA) submitted under ...
RALEIGH (WTVD) -- The I-Team investigates a drug that thousands of women take for many female medical problems. The I-Team discovered many patients report numerous side effects after taking Lupron. A ...
The FINANCIAL — Abbott Park, Illinois — Abbott announced today that the U.S. Food and Drug Administration (FDA) has approved a new 45 mg for six-month administration formulation of Lupron Depot® ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback